[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
December 2014

The Debate on Antibiotic Therapy for Patients Hospitalized for PneumoniaWhere Should We Go From Here?

Author Affiliations
  • 1Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
  • 2Veterans Affairs Pittsburgh Healthcare System, Center for Health Equity Research and Promotion, Pittsburgh, Pennsylvania
JAMA Intern Med. 2014;174(12):1901-1903. doi:10.1001/jamainternmed.2014.3996

Although our understanding of pneumonia dates back thousands of years to when symptoms were recognized by Hippocrates, the first typical bacterial pathogen responsible for causing community-acquired pneumonia (CAP), Streptococcus pneumoniae, was not isolated until the late 19th century. Another half a century passed before 3 atypical bacteria were discovered as pneumonia pathogens (ie, Mycoplasma pneumoniae in 1944, Legionella species in 1976, and Chlamydia pneumoniae in 1981). Meanwhile, treatment for CAP only became available in the 1940s with the advent of penicillin followed by cephalosporins. Although macrolides were discovered in the 1950s, newer-generation drugs in this class now commonly used to treat CAP (eg, azithromycin and clarithromycin) were approved by the Food and Drug Administration in the early 1990s. Similarly, although discovered in the 1960s, advanced-generation respiratory fluoroquinolones (eg, levofloxacin, moxifloxacin, and gemifloxacin) were approved between 1996 and 2003.

First Page Preview View Large
First page PDF preview
First page PDF preview
×